AhangaraniR.R., JanssensW., VanderElstL.et al.2009. In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. J. Immunol., 183:8232–8243.
2.
BoudreauJ.E., BonehillA., ThielemansK., WanY.2011. Engineering dendritic cells to enhance cancer immunotherapy. Mol. Ther., 19:841–853.
3.
BreousE., SomanathanS., VandenbergheL.H., WilsonJ.M.2009. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology, 50:612–621.
CaoO., HoffmanB.E., MoghimiB.et al.2009. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol. Ther., 17:1733–1742.
6.
CerulloV., McCormackW., SeilerM.et al.2007. Antigen-specific tolerance of human α1-antitrypsin induced by helper-dependent adenovirus. Hum. Gene Ther., 18:1215–1224.
7.
CooperM., NayakS., HoffmanB.E.et al.2009. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum. Gene Ther., 20:767–776.
8.
Di MicheleD.M.2011. Immune tolerance induction in haemophilia: Evidence and the way forward. J. Thromb. Haemost., 9,Suppl. 1:216–225.
HoffmanB.E., MartinoA.T., SackB.K.et al.2011. Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol. Ther., 19:1263–1272.
11.
KimS.H., BiancoN.R., ShufeskyW.J.et al.2007. MHC class II+ exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner. J. Immunol., 179:2235–2241.
12.
LiuC.L., YeP., YenB.C., MiaoC.H.2011. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol. Ther., 19:1511–1520.
13.
LoDucaP.A., HoffmanB.E., HerzogR.W.2009. Hepatic gene transfer as a means of tolerance induction to transgene products. Curr. Gene Ther., 9:104–114.
14.
MiaoC.H.2011. Advances in overcoming immune responses following hemophilia gene therapy. J. Genet. Syndr. Gene Ther.S1, 007.
15.
MoghimiB., SackB.K., NayakS.et al.2011. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J. Thromb. Haemost., 9:1524–1533.
16.
PaluckaK., BanchereauJ.2012. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer, 12:265–277.
17.
SackB.K., MerchantS., MarkusicD.M.et al.2012. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One, 7:e37671.
18.
SkupskyJ., ZhangA.H., SuY., ScottD.W.2010. B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol. Ther., 18:1527–1535.
19.
SteinmanR.M., CohnZ.A.1973. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med., 137:1142–1162.
20.
SuR.J., EppA., FengJ.et al.2011. Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells. Mol. Ther., 19:1896–1904.
21.
SuleG., SuzukiM., GuseK.et al.2012. Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice. Hum. Gene Ther.(this issue).
22.
VermaD., MoghimiB., LoDucaP.A.et al.2010. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc. Natl. Acad. Sci. U.S.A., 107:7101–7106.
23.
ZakasP.M., SpencerH.T., DoeringC.B.2011. Engineered hematopoietic stem cells as therapeutics for hemophilia A. J. Genet. Syndr. Gene Ther.S1, 003.
24.
ZhangA.H., SkupskyJ., ScottD.W.2011. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood, 117:2223–2226.
